Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 23, Issue 10, Pages 899-906Publisher
JOHN WILEY & SONS INC
DOI: 10.1002/hed.1130
Keywords
murine model; SCCVII; cancer immunotherapy
Categories
Funding
- NIDCR NIH HHS [1 K23 DE00459-01] Funding Source: Medline
Ask authors/readers for more resources
Background. To develop novel therapeutic approaches for patients with head and neck malignancies, poorly immunogenic murine models of squamous cell carcinoma (SCC) need to be defined. Methods. The phenotype, growth characteristics, and responsiveness to tumor-specific T-cell transfer of a spontaneously arising murine SCC (SCC VII) were characterized. Results. SCC VII expresses major histocompatibility complex (MHC) class I molecules yet is resistant to tumor-specific T-cell killing and relatively insensitive to killing mediated by lymphokine-activated killer (LAK) cells. Intradermal tumors are reproducibly established after vaccination of 5 x 10(4) cells, and systemic micrometastases are apparent after intravenous administration of 2.5 x 10(4) Cells. Immunotherapy of 3-day lung metastases using tumor-specific T cells and systemic interleukin-2 (IL-2) was ineffective in reducing the number of metastases in vivo. Conclusions. SCC VII is a poorly Immunogenic murine squamous cell cancer, which represents an ideal model for preclinical testing of immunotherapeutic, approaches for patients with SCC of the upper aerodigestive tract. (C) 2001 John Wiley & Sons, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available